Efficacy and Safety of Rituximab Versus Inebilizumab in Patients With Neuromyelitis Optica Spectrum Disorder: A Dual‐Center, Real‐World Cohort Study

医学 美罗华 队列 入射(几何) 内科学 视神经脊髓炎 队列研究 光谱紊乱 肿瘤科 回顾性队列研究 抗体疗法 儿科 免疫学
作者
Ying Cui,Zihao Yu,Hengri Cong,Hao Zhang,Yutong Shi,Ai Guo,Yujing Li,Dongmei Jia,Chao Zhang,Kaibin Shi,Fu‐Dong Shi,Wei Jiang
出处
期刊:European Journal of Neurology [Wiley]
卷期号:33 (3): e70545-e70545 被引量:2
标识
DOI:10.1111/ene.70545
摘要

BACKGROUND: This study aimed to compare the real-world efficacy and safety of rituximab and inebilizumab in patients with aquaporin-4 immunoglobulin G (AQP4-IgG) seropositive neuromyelitis optica spectrum disorder (NMOSD). METHODS: This retrospective study included patients treated with rituximab or inebilizumab at two tertiary hospitals in China between January 2015 and June 2025. Propensity score matching was conducted to reduce between-group imbalance. The primary endpoint was time to first confirmed relapse. Secondary outcomes included changes in annualized relapse frequency, EDSS scores, and serum IgG and AQP4-IgG levels. Safety profiles were also assessed. RESULTS: A total of 276 patients were analyzed (rituximab: 211; inebilizumab: 65), yielding 61 well-balanced pairs after propensity score matching. In terms of efficacy, clinical outcomes and AQP4-IgG dynamics were comparable between groups in pre- and post-matching analyses, although inebilizumab exhibited a significantly greater reduction in serum IgG levels at 6 months. Safety profiles differed. Rituximab was associated with a higher incidence of overall adverse events, driven primarily by infusion-related reactions, whereas other adverse events remained comparable. CONCLUSIONS: In our real-world study of 276 patients, rituximab and inebilizumab demonstrated comparable efficacy in the medium term but differed in their safety profiles, with a significantly higher incidence of infusion-related reactions observed in the rituximab group.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
KMS完成签到,获得积分10
1秒前
moon发布了新的文献求助10
1秒前
1秒前
白芷完成签到,获得积分10
1秒前
Luna完成签到 ,获得积分10
3秒前
晓天发布了新的文献求助10
3秒前
3秒前
Jasper的应助被璐璐采纳,获得10
3秒前
桐桐的应助被冰棍采纳,获得10
3秒前
桐桐的应助被冰棍采纳,获得10
4秒前
JamesPei的应助被姜OMG采纳,获得10
4秒前
琪琪完成签到 ,获得积分10
4秒前
小波儿发布了新的文献求助10
4秒前
唐唐发布了新的文献求助10
4秒前
5秒前
5秒前
领导范儿的应助被困告采纳,获得10
7秒前
斯多姆发布了新的文献求助10
7秒前
大个的应助被www采纳,获得10
7秒前
乐正亦寒完成签到 ,获得积分10
8秒前
完美世界的应助被wba采纳,获得30
8秒前
8秒前
道鹏完成签到,获得积分10
9秒前
10秒前
快乐的如曼完成签到 ,获得积分10
10秒前
777发布了新的文献求助10
10秒前
Flaubert发布了新的文献求助10
11秒前
march的应助被亲爱的安德烈采纳,获得10
12秒前
狮子完成签到,获得积分20
12秒前
13秒前
不安易文完成签到,获得积分10
14秒前
斯多姆完成签到,获得积分10
14秒前
彭于彦祖的应助被sweetwan采纳,获得50
15秒前
图图完成签到 ,获得积分10
15秒前
jade完成签到,获得积分10
16秒前
白春蕾发布了新的文献求助10
16秒前
jiangsi完成签到 ,获得积分10
16秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527